Demonstration of the preclinical correlate of protection for Staphylococcus aureus clumping factor A in a murine model of infection

Vaccine

Volumn 33, Issue 41, 2015, Pages 5452-5457

  Scully, Ingrid L ^a   Timofeyeva, Yekaterina ^a   Keeney, David ^a   Matsuka, Yury V ^a   Severina, Elena ^a   McNeil, Lisa K ^a   Nanra, Jasdeep ^a   Hu, George ^b   Liberator, Paul A ^a   Jansen, Kathrin U ^a   Anderson, Annaliesa S ^a  

^a Vaccine Research East and Early Development   (United States)

^b Pfizer Drug Safety Research and Development   (United States)

Author keywords

Clumping factor A; Correlate of protection; Fibrinogen binding; Staphylococcus aureus; Virulence factor

Indexed keywords

ANTIBODY; BACTERIAL VACCINE; CLUMPING FACTOR A MONOCLONAL ANTIBODY; FIBRINOGEN; RECOMBINANT CLUMPING FACTOR A; UNCLASSIFIED DRUG; VIRULENCE FACTOR; BACTERIUM ANTIBODY; CLFA PROTEIN, STAPHYLOCOCCUS AUREUS; COAGULASE; PROTEIN BINDING; RECOMBINANT PROTEIN;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HETEROLOGOUS EXPRESSION; IN VIVO STUDY; LACTOCOCCUS LACTIS; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN BINDING; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS INFECTION; ANIMAL; BLOOD; DISEASE MODEL; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; STAPHYLOCOCCAL INFECTIONS; VIRULENCE;

ANIMALS; ANTIBODIES, BACTERIAL; COAGULASE; DISEASE MODELS, ANIMAL; FIBRINOGEN; HUMANS; IMMUNIZATION; LACTOCOCCUS LACTIS; MICE; PROTEIN BINDING; RECOMBINANT PROTEINS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VIRULENCE;

EID: 84941876351     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.08.029     Document Type: Article

References (22)

1. Kluytmans J., van Belkum A., Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997, 10(3):505-520.
2. Noskin G.A., Rubin R.J., Schentag J.J., Kluytmans J., Hedblom E.C., Smulders M., et al. The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med 2005, 165(15):1756-1761.
3. McDevitt D., Francois P., Vaudaux P., Foster T.J. Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) of Staphylococcus aureus. Mol Microbiol 1995, 16(5):895-907.
4. McDevitt D., Nanavaty T., House-Pompeo K., Bell E., Turner N., McIntire L., et al. Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen. Eur J Biochem 1997, 247(1):416-424.
5. O'Brien L., Kerrigan S.W., Kaw G., Hogan M., Penades J., Litt D., et al. Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus: roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A. Mol Microbiol 2002, 44(4):1033-1044.
6. McAdow M., Kim H.K., Dedent A.C., Hendrickx A.P., Schneewind O., Missiakas D.M. Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood. PLoS Pathog 2011, 7(10):pe1002307.
7. Josefsson E., Hartford O., O'Brien L., Patti J.M., Foster T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 2001, 184(12):1572-1580.
8. Moreillon P., Entenza J.M., Francioli P., McDevitt D., Foster T.J., Francois P., et al. Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis. Infect Immun 1995, 63(12):4738-4743.
9. Hawkins J., Kodali S., Matsuka Y.V., McNeil L.K., Mininni T., Scully I.L., et al. A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure. Clin Vaccine Immunol 2012, 19(10):1641-1650.
10. Kaufman D. Veronate (Inhibitex). Curr Opin Investig Drugs 2006, 7(2):172-179.
11. Que Y.A., Francois P., Haefliger J.A., Entenza J.M., Vaudaux P., Moreillon P. Reassessing the role of Staphylococcus aureus clumping factor and fibronectin-binding protein by expression in Lactococcus lactis. Infect Immun 2001, 69(10):6296-6302.
12. Que Y.A., Haefliger J.A., Francioli P., Moreillon P. Expression of Staphylococcus aureus clumping factor A in Lactococcus lactis subsp. cremoris using a new shuttle vector. Infect Immun 2000, 68(6):3516-3522.
13. Hall A.E., Domanski P.J., Patel P.R., Vernachio J.H., Syribeys P.J., Gorovits E.L., et al. Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect Immun 2003, 71(12):6864-6870.
14. Hair P.S., Ward M.D., Semmes O.J., Foster T.J., Cunnion K.M. Staphylococcus aureus clumping factor A binds to complement regulator factor I and increases factor I cleavage of C3b. J Infect Dis 2008, 198(1):125-133.
15. Hair P.S., Echague C.G., Sholl A.M., Watkins J.A., Geoghegan J.A., Foster T.J., et al. Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis. Infect Immun 2010, 78(4):1717-1727.
16. Loughman A., Fitzgerald J.R., Brennan M.P., Higgins J., Downer R., Cox D., et al. Roles for fibrinogen, immunoglobulin and complement in platelet activation promoted by Staphylococcus aureus clumping factor A. Mol Microbiol 2005, 57(3):804-818.
17. Ganesh V.K., Rivera J.J., Smeds E., Ko Y.P., Bowden M.G., Wann E.R., et al. A structural model of the Staphylococcus aureus ClfA-fibrinogen interaction opens new avenues for the design of anti-staphylococcal therapeutics. PLoS Pathog 2008, 4(11):pe1000226.
18. Flick M.J., Du X., Prasad J.M., Raghu H., Palumbo J.S., Smeds E., et al. Genetic elimination of the binding motif on fibrinogen for the S. aureus virulence factor ClfA improves host survival in septicemia. Blood 2013, 121(10):1783-1794.
19. Harrington G., Russo P., Spelman D., Borrell S., Watson K., Barr W., et al. Surgical-site infection rates and risk factor analysis in coronary artery bypass graft surgery. Infect Control Hosp Epidemiol 2004, 25(6):472-476.
20. Berbari E.F., Hanssen A.D., Duffy M.C., Steckelberg J.M., Ilstrup D.M., Harmsen W.S., et al. Risk factors for prosthetic joint infection: case-control study. Clin Infect Dis 1998, 27(5):1247-1254.
21. Mangram A.J., Horan T.C., Pearson M.L., Silver L.C., Jarvis W.R. Guideline for prevention of surgical site infection, 1999. Centers for disease control and prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1999, 27(2):97-132. (quiz 133-4; discussion 96).
22. Vernachio J.H., Bayer A.S., Ames B., Bryant D., Prater B.D., Syribeys P.J., et al. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob Agents Chemother 2006, 50(2):511-518.